Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
about
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled studyThe clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerA case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resectionScreening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the questionOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsAn individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic ReviewPhase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer.Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.Metastatic colorectal cancer: systemic treatment in the new millennium.Health-related quality of life in colorectal cancer patients.Review article: colorectal cancer chemotherapy.Progress in the medical treatment of advanced colorectal cancer.A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.Developments in treatment of primary irresectable rectal cancer.Feasibility of 5-days-on/2-days-off UFT/leucovorin in post-operative long-term adjuvant chemotherapy for colorectal cancer.Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled TrialCurrent stage-specific chemotherapeutic options in colon cancer.Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerDrug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'Chemotherapy for elderly patients with advanced colorectal carcinoma.Optimal treatment of metastatic colorectal cancer.Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II studyFailure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I studyPhase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancerDocetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
P2860
Q24645666-EA4E3382-81D4-4E6F-A4A4-D88A117ACB75Q24652904-8854F10D-7EE5-4EC1-8867-3F3B276951DAQ25257549-C5F65198-B65A-4807-8C47-2805A0D76B0CQ28301967-3691CC69-0024-4F59-8D10-EB80D25A6FF6Q30913489-58A09425-CD80-4ABC-9B89-7FE2218324CAQ31106341-AB0C3835-8F13-4974-B9B3-DB30F1DB732FQ31125157-B4258880-69D8-4CDC-AEC6-27139F8186C1Q33363451-B8896EED-998C-425C-8DAA-4F995E826FB8Q33437668-9F6FDFE3-6374-46E7-9D8F-F4B0EBC50925Q33442681-0270C8AC-78EB-4E7E-8837-9A9A72170243Q33522017-4CD2405C-D244-451C-8199-355CB7BCD931Q33710348-BEC836ED-3E5A-4710-A4EF-FF3871410793Q33727059-C16527DB-4070-4CE4-AA12-78F0886389DAQ33751177-DD058EAC-A3E0-46B6-A8E5-4058ACF75AABQ35041996-B298AFFC-A8B8-435D-83B7-2075CEE2C159Q35097975-720FDCA7-AE72-43C5-B084-9D4354E2F928Q35148795-FB41F127-5560-41F6-9B7E-C8A9E56C6DF7Q35204956-A97F1694-C052-42A8-8371-279242984F7BQ35544078-C925ED70-4D07-45D1-8B74-D1914E983762Q35576191-55AE6A02-AF47-4BE2-96F4-10E7DDAF4DF8Q35756882-C9DB6717-3737-42A1-8662-694E69D3DB9EQ35937087-CA440687-8B48-441F-B633-B50A82204676Q35995117-40865D10-92F2-4A9C-8531-0B0ABA4F2DFBQ36061168-3D47741C-838F-48C4-B953-C0C5B04758F0Q36121535-6EEA62A2-1ABC-46BE-8570-831388E3C489Q36235576-1B42D72F-E6E9-4AEE-BDA0-478EB06BE230Q36300533-06E25118-A4BE-4A35-8A3E-E1242048C317Q36306269-AB7298E0-7F44-4EFB-A940-BF188A2237D0Q36318341-803D38EA-E908-4802-BAAB-6D873EC5A1C1Q36324953-36A9C83A-0A9E-45F1-88FD-2C5735A074C9Q36365078-C52EB40A-981C-49CF-AB27-A82B9C849C21Q36499252-28195D7D-E733-459B-B9EC-6ADB50246217Q36499255-30385F65-0C87-470E-934C-271A33F9EC98Q36515540-AC6922B6-16A2-40E1-9FB1-06EB5D2C0754Q36609827-0C5E7271-93FF-481F-9E7E-CB329AA84A8FQ36609950-86617526-A929-494C-8AF4-ACFF3961CFACQ36610544-6E7DDD88-3DB0-4F24-B5BC-5CB41DF21B7DQ36610970-54EDC538-A26B-4F51-8ECB-5711F5A467E6Q36616308-563D1A64-09C2-4C1E-BC03-0671E746E636Q36694455-C88DBA8F-59F2-40E9-815A-5065DDA32482
P2860
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Multicenter phase III study of ...... metastatic colorectal cancer.
@en
Multicenter phase III study of ...... metastatic colorectal cancer.
@nl
type
label
Multicenter phase III study of ...... metastatic colorectal cancer.
@en
Multicenter phase III study of ...... metastatic colorectal cancer.
@nl
prefLabel
Multicenter phase III study of ...... metastatic colorectal cancer.
@en
Multicenter phase III study of ...... metastatic colorectal cancer.
@nl
P2093
P356
P1476
Multicenter phase III study of ...... metastatic colorectal cancer.
@en
P2093
Antonella Maniero
Barry C Lembersky
Jamey R Skillings
Mark D Vincent
Neville Davidson
Paulo M Hoff
Peter Eisenberg
Peter Harper
Seth Thompson
Steven E Benner
P304
P356
10.1200/JCO.2002.04.123
P407
P577
2002-09-01T00:00:00Z